Table 1.

Demographics of the ALK inhibitor cohort

	Overall	No tumor shrinkage	1%–25%	26%–50%	51%–75%	76%–100%
	(n = 305)	(n = 12)	(n = 39)	(n = 70)	(n = 144)	(n = 40)
Age
Median	51	57	53	49	50	50
Range	22, 81	41, 68	25, 73	22, 78	22, 81	29, 73
Gender
Male	131 (43%)	7 (58%)	20 (51%)	32 (46%)	62 (43%)	10 (25%)
Female	174 (57%)	5 (42%)	19 (49%)	38 (54%)	82 (57%)	30 (75%)
Race
White	158 (52%)	2 (17%)	25 (64%)	43 (61%)	70 (49%)	18 (45%)
Black or AA	2 (<1%)	0	1 (3%)	0	1 (<1%)	0
Asian	140 (46%)	10 (83%)	13 (33%)	26 (37%)	69 (48%)	22 (55%)
Other	5 (2%)	0	0	1 (1%)	4 (3%)	0
Region
USA	36 (12%)	0	6 (15%)	10 (14%)	17 (12%)	3 (8%)
Non-USA	269 (88%)	12 (100%)	33 (85%)	60 (86%)	127 (88%)	37 (92%)
ECOG PS
0	119 (39%)	5 (42%)	15 (38%)	30 (43%)	57 (40%)	12 (30%)
1	169 (55%)	6 (50%)	23 (59%)	35 (50%)	78 (54%)	27 (68%)
2	17 (6%)	1 (8%)	1 (3%)	5 (7%)	9 (6%)	1 (3%)
Smoking status
Current/former	114 (37%)	7 (58%)	14 (36%)	26 (37%)	61 (42%)	6 (15%)
Never	191 (63%)	5 (42%)	25 (64%)	44 (63%)	83 (58%)	34 (85%)